Dr. Matthew Streetly is a Consultant Haematologist and clinical lead for myeloma/plasma cell disorders. He has a special interest in the use of novel therapies for patients with myeloma and is the principal investigator on multiple clinical trials. Dr. Streetly is a member of the UK myeloma forum guidelines writing group and a special trustee of the British Society of Haematology. He has published widely on myeloma and related disorders and is an invited speaker at national and international meetings. His expertise includes clinical trials for novel therapies for myeloma, myeloma diagnostics and biomarkers, haematology, myeloma and other plasma cell disorders (Amyloidosis, MGUS), stem cell transplant, and lymphoma.